Tumor Necrosis Factor

The addition of a tumor necrosis factor inhibitor to steroid therapy reduced acute stage disease duration and hospital stay in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, according to a study.

Exposure to TNF inhibitors nearly triples the risk for psoriasis among children with juvenile idiopathic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.

The largest dataset of U.S. patients with Behçet’s disease to date shows that nearly 80% are women, according to researchers who published their findings in Arthritis Research & Therapy.

Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.

Patients being treated with tumor necrosis factor inhibitors or methotrexate who acquired COVID-19 did not experience elevated hospitalization or mortality rates, according to a study.

Time moves in funny ways in medicine. Physicians and researchers can work for decades in obscurity on a cure for a particular disease and make little progress. But once the critical breakthrough comes, 6 months or a year can change everything.

Children with inflammatory bowel disease, juvenile idiopathic arthritis and chronic noninfectious osteomyelitis had an increased rate of psoriasis, and those exposed to tumor necrosis factor inhibitor therapy exhibited the highest risk, according to research presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.

This ripping yarn delves into the history of tumor necrosis factor in relation to rheumatoid arthritis with emphasis on the original studies that set the stage for the use of TNF inhibition in RA.